Main menu button

Carlsquare facilitated Frank Otto’s multi-million investment in SynBiotic SE, while advising Frank Otto and the other shareholders of CannaCare Health GmbH on its merger with SynBiotic SE

Serial entrepreneur Frank Otto has invested in SynBiotic SE (“SynBiotic”), one of Germany’s leading listed CBD specialists. Frank Otto’s investment comes as the SynBiotic group merges with CBD specialist CannaCare Health GmbH, where Frank Otto is the single largest shareholder today. As part of his investment, Frank Otto will become a major shareholder in SynBiotic, reflecting his confidence that SynBiotic will secure a pre-eminent position in the booming market for hemp products.

Hamburg-based CannaCare GmbH markets its products under the brand “Canobo®”. Canobo® is now the leading German brand for premium cannabinoid-based (CBD) health, wellness, and skin-care products. Overall, Canobo® is one of the top five CBD brands in Germany. It is sold across the country, including in more than 2400 outlets of leading drugstore chains like Rossmann and Budnikowsky, in pharmacies, on HSE24, Germany’s largest TV shopping channel, and on online marketplaces.

Munich-based SynBiotic is a listed group of companies in the hemp and cannabis sector. The group has an EU-focused buy & build investment strategy. It is involved in all phases of the supply chain from cultivation to production to retail. The core businesses of this vertically-integrated company are research & development, the production of hemp, CBD and cannabis products, and their marketing.

I see SynBiotic as the future of the European cannabis industry. No other group of companies looks at this exciting market as holistically. When Michael Oplesch, whom I know through our joint founding of VIVA, approached me about hemp, cannabis and CBD a few years ago, I was immediately excited. For decades, my aim as an entrepreneur has been to to make the world a better and more sustainable place through business success.” – Frank Otto, Investor CannaCare Health 

Carlsquare has a long-standing relationship with CannaCare Health, facilitating a multi-million growth investment in 2019. In this and other transactions, Carlsquare has acted as the exclusive Financial Advisor for CannaCare and its shareholders.

CannaCare Health GmbH
Synbiotec SE